Exagen Beats Q2 Revenue by 12%, Raises 2026 Outlook on Test Volume Surge
XGN has more than doubled off its 52-week low of $2.59.
Summary
Exagen delivered a strong Q2, with revenue of $19.94M beating consensus by 12% on 11% test volume growth and a 4% ASP increase. The company raised full-year 2026 revenue guidance to $72M-$75M, signaling confidence in sustained demand for its AVISE lupus diagnostics. Net loss narrowed nearly 30% to $3.2M, and adjusted EBITDA loss shrank to just $0.1M, putting breakeven within reach. This follows a Q1 beat in May and recent validation of AVISE Lupus performance, reinforcing the commercial momentum. With a $113M market cap and shares at $5.60, the raised outlook and improving margins could drive further re-rating.
At the time of this announcement, XGN was trading at $5.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $113.1M. The 52-week trading range was $2.59 to $12.23. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.